[1]
Orekhov, A.N.; Sobenin, I.A. Modified and Dysfunctional Lipoproteins in Atherosclerosis: Effectors or Biomarkers? Curr. Med. Chem., 2019, 1512-1524.
[2]
Arnao, V.; Tuttolomondo, A.; Daidone, M.; Pinto, A. Lipoproteins in Atherosclerosis Process. Curr. Med. Chem., 2019, 1525-1543.
[3]
Chroni, A.; Kardassis, D. HDL Dysfunction Caused by Mutations in apoA-I and Other Genes that are Critical for HDL Biogenesis and Remodeling. Curr. Med. Chem., 2019, 1544-1575.
[4]
Itabe, H.; Kato, R.; Sasabe, N.; Obama, T.; Yamamoto, M. The Significance of Oxidized Low-Density Lipoprotein in Body Fluids as a Marker Related to Diseased Conditions. Curr. Med. Chem., 2019, 1576-1593.
[5]
Schnitzler, J.G.; Dallinga-Thie, G.M.; Kroon, J. The Role of (Modified) Lipoproteins in Vascular Function: A Duet Between Monocytes and the Endothelium. Curr. Med. Chem., 2019, 1594-1609.
[6]
Ossoli, A.; Pavanello, C. Giorgio, E.; Calabresi, L.; Gomaraschi, M. Dysfunctional HDL as a Therapeutic Target for Atherosclerosis Prevention. Curr. Med. Chem., 2019, 1610-1630.
[7]
Miyazaki, T.; Miyazaki, A. Impact of Dysfunctional Protein Catabolism on Macrophage Cholesterol Handling. Curr. Med. Chem., 2019, 1631-1643.
[8]
Pirillo, A.; Catapano, A.L.; Norata, G.D. Biological Consequences of Dysfunctional HDL. Curr. Med. Chem., 2019, 1644-1664.
[9]
Rivas-Urbina, A.; Rulla, A.; Ordóñez-Llanosa, J.; Sánchez-Quesada, J.L. Electronegative LDL: An Active Player in Atherogenesis or a By-Product of Atherosclerosis? Curr. Med. Chem., 2019, 1665-1679.
[10]
Lopes-Virella, M.F.; Virella, G. Modified LDL Immune Complexes and Cardiovascular Disease. Curr. Med. Chem., 2019, 1680-1692.